Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin

Epilepsy Research

Volumn 82, Issue 1, 2008, Pages 86-92

  Briggs, Deborah E ^a   Lee, Caroline M ^b   Spiegel, Katharyn ^b   French, Jacqueline A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Placebo controlled study; Pregabalin; Refractory partial epilepsy; Secondarily generalized tonic clonic; Seizure reduction

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO; PREGABALIN; 4 AMINOBUTYRIC ACID; DRUG DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; GRAND MAL SEIZURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; DOSE RESPONSE; FOCAL EPILEPSY; META ANALYSIS; MULTIDRUG RESISTANCE; SALVAGE THERAPY; SEIZURE; STATISTICS;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MULTIPLE; EPILEPSIES, PARTIAL; GAMMA-AMINOBUTYRIC ACID; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SEIZURES;

EID: 64149132484     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.07.004     Document Type: Article

References (11)

1. Arroyo S., Anhut H., Kugler A.R., et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45 (2004) 20-27
2. Beydoun A., Uthman B.M., Kugler A.R., et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64 (2005) 475-480
3. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 34 (1999) 1-41
4. Errante L.D., and Petroff O.A. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 12 (2003) 300-306
5. Field M.J., Oles R.J., and Singh L. Pregabalin may represent a novel class of anxiolytics agents with a broad spectrum of activity. Br. J. Pharmacol. 132 (2001) 1-4
6. Fink K., Dooley D.J., Meder W.P., et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42 (2002) 229-236
7. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., and Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60 (2003) 1631-1637
8. Leppik I.E., Biton V., Sander J.W., and Wieser H.G. Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials. Epilepsia 44 (2003) 1585-1587
9. Piechan, J.L., Donevan, S., Taylor, C., Dickerson, M., Li, Z., 2004. Pregabalin, a novel anticonvulsant, analgesic, and anxiolytic drug, exhibits class-specific α2δ-1 and α2δ-2 calcium channel subunit binding [abstract 115.11]. 2004 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC. Available via: http://sfn.scholarone.com/itin2004/ (accessed November 14, 2007).
10. Taylor C.P., Vartanian M.G., Yuen P.W., Bigge C., Suman-Chauhan N., and Hill D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 14 (1993) 11-15
11. Vartanian M.G., Radulovic L.L., Kinsora J.J., et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68 (2006) 189-205